1. Home
  2. AQB vs SHPH Comparison

AQB vs SHPH Comparison

Compare AQB & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

HOLD

Current Price

$1.03

Market Cap

3.3M

Sector

N/A

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

HOLD

Current Price

$1.48

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQB
SHPH
Founded
1991
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
AQB
SHPH
Price
$1.03
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.4K
494.6K
Earning Date
10-28-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.26
52 Week High
$2.95
$25.25

Technical Indicators

Market Signals
Indicator
AQB
SHPH
Relative Strength Index (RSI) 57.27 N/A
Support Level $0.87 N/A
Resistance Level $1.09 N/A
Average True Range (ATR) 0.09 0.00
MACD 0.03 0.00
Stochastic Oscillator 76.92 0.00

Price Performance

Historical Comparison
AQB
SHPH

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Share on Social Networks: